As part of an ongoing multistate investigation, CDC is attempting to identify hospitals that have detected clusters of Burkholderia cepacia (B. cepacia) cases among pediatric or adult ICU patients, particularly since January 2016. To report clusters, please contact the CDC Division of Healthcare Quality Promotion Outbreak Email box at:


General Information about B. cepacia
Burkholderia cepacia [burk–hōld–er–uh  si–pay–shee–uh] (also called B. cepacia) is the name for a group or “complex” of bacteria that can be found in soil and water. B. cepacia bacteria are often resistant to common antibiotics. B. cepacia poses little medical risk to healthy people. However, people who have certain health problems such as weakened immune systems or chronic lung diseases, particularly cystic fibrosis, are more susceptible to this bacteria. B. cepacia is a known cause of infections in hospitalized patients.

For additional information on B. cepacia please visit



Update June 29, 2016

Preliminary information continues to indicate that contaminated oral ‎liquid docusate products might be related to B. cepacia complex infections in one state. At this time, there is no epidemiologic or laboratory evidence to suggest oral capsules or enemas are affected. Until more information is available, CDC continues to recommend that facilities not use any oral liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Facilities that experience B. cepacia complex infections among non-cystic fibrosis patients or clusters of B. cepacia complex infections among cystic fibrosis patients should sequester all oral liquid docusate products.‎‎

Healthcare providers and laboratories should remain on alert for B. cepacia complex infections occurring among non-cystic fibrosis patients and should inform infection prevention staff when these infections occur. In addition, clusters of B. cepacia complex infections among patients with CF should be reported when infection rates appear above endemic rates. Cases should be reported to state or local public health authorities.

CDC will provide an update to this announcement by July 7. Please direct questions to CDC at